中国临床药理学杂志2018，Vol.34Issue(2)：177-180,4.DOI:10.13699/j.cnki.1001-6821.2018.02.023
双膦酸盐用于老年性骨质疏松治疗有效性和安全性的系统评价
Efficacy and safety of bisphosphonates for senil osteoporosis: A systematic review
李萍 1李潇潇 2赵荣生1
作者信息
- 1. 北京大学第三医院药剂科,北京100191
- 2. 中国药科大学药学院,南京211198
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of bisphosphonates in patients with senil osteoporosis.Methods Several databases including PubMed,EmBase,Cochrane Central Register of Controlled Trials,CNKI,VIP and Wanfang databases were searched to collect randomized controlled trials (RCTs) related to bisphosphonates for treating senil osteoporosis from inception to April 2017.All RCTs about anti-osteoporosis treatment of bisphosphonates in patients with senile osteoporosis were selected.The quality of included studies was evaluated,and Meta analysis was performed using Revman 5.3 software.Results A total of 11 RCTs were enrolled in the analysis.Compared with the control group,the risk of hip (RR =0.72,95％ CI:0.56-0.92,P ＜ 0.01)or vertebral (RR =0.57,95 ％ C1:0.38-0.84,P ＜ 0.01)fractures were reduced significantly in the bisphosphonates group (all P ＜ 0.05).Subgroup analysis shows that treating hip fractures,significant differences existed between oral bisphosphonates group and control group(P ＜ 0.05),but disappeared between intravenous bisphosphonates group and control goup(P ＞ 0.05).There were no significant differences in the rates of total adverse reactions and serious adverse events between the two groups (all P ＞ 0.05).Conclusion Bisphosphonates could effectively decrease the risk of hip and vertebral fractures,but not increase the incidences of adverse drug reactions and serious adverse events.关键词
双膦酸盐/老年性骨质疏松/Meta分析Key words
bisphosphonates/senile osteoporosis/Meta-analysis分类
医药卫生引用本文复制引用
李萍,李潇潇,赵荣生..双膦酸盐用于老年性骨质疏松治疗有效性和安全性的系统评价[J].中国临床药理学杂志,2018,34(2):177-180,4.
